Diseases Studied
The Rare Diseases Clinical Research Network is an NIH-funded research network of 20 active consortia or research groups working to advance treatment for diseases that are rare. Use the search tools on this page to find the diseases we currently study. You can reach out to the indicated consortia or research groups for more information on those diseases and studies underway.
This network focuses on clinical research and does not generally support clinical care outside of research activities. To learn about other rare diseases, please visit the Genetic and Rare Diseases Information Center (GARD), which is an NIH program that helps the public find reliable information about rare and genetic diseases. Their staff are specialists. Contact them at 1-888-205-2311 or email GARDinfo@nih.gov.
All Diseases > NGLY1 deficiency
NGLY1 deficiency (NGLY1-CDDG)
Alternative Names: NGLY1 Congenital Disorder of Deglycosylation
Disease Category: Congenital Disorders of Glycosylation
A rare, inherited condition caused by an abnormal enzyme disrupting N-linked deglycosylation. Symptoms manifest during infancy, including hypotonia (low muscle tone), seizures, liver disease, eye problems, failure to thrive, hyperkinetic movements, motor and speech delays, peripheral neuropathy, apnea, hypohydrosis, hearing loss, hypermobile joints, and scoliosis.
Research groups studying this disease
Congenital Disorders of Glycosylation
Frontiers in Congenital Disorders of Glycosylation (FCDGC)
Recruiting
8401: Clinical and Basic Investigations into Congenital Disorders of Glycosylation
The investigators are conducting a natural history study of patients with congenital disorders of glycosylation (CDG). The study will look into the progression of the disease amongst the participants and also look at the clinical symptoms and how they vary amongst different diseased population groups. The participants will be asked to fill out questionnaires either on their own or with a provider that will grade the severity of disease and document symptoms and diet. Participants will have an opportunity to submit blood, urine, and stool samples that will be tested for biomarkers for CDG. Participants will also complete dietary food records, physical exams, CDG scores, and the PROMIS questionnaires to assess disease progression and severity.
Not Yet Recruiting
8404: A Phase II Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Effect of GLCNAC on Tear Production in Individuals with NGLY1-CDDG
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG
CDG CARE (Community Alliance and Resource Exchange)
Promotes awareness of congenital disorders of glycosylation (CDG) and NGLY1-deficiency, provides resources, and funds scientific research.
CDG Canada
Connects patients and families affected by congenital disorders of glycosylation (CDG) to clinicians and researchers in Canada and globally.